$PCVX (VAXCYTE) — 8-K: Vaxcyte narrows VAX-31 OPUS-1 topline data guidance to end of October 2026

Vaxcyte appointed Luis Jodar, Ph.D. as Chief Medical Officer and David McAvoy, J.D. as Chief Legal Officer. The Company now expects topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 pivotal trial by the end of October 2026, narrowing prior fourth quarter guidance. Dr. Jodar previously served as Pfizer’s Chief Medical Officer for Vaccines and Infectious Diseases, with leadership experience across Prevnar 13 and Prevnar 20.

Vaxcyte appointed Luis Jodar, Ph.D. as Chief Medical Officer and David McAvoy, J.D. as Chief Legal Officer. The Company now expects topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 pivotal trial by the end of October 2026, narrowing prior fourth quarter guidance. Dr. Jodar previously served as Pfizer’s Chief Medical Officer for Vaccines and Infectious Diseases, with leadership experience across Prevnar 13 and Prevnar 20.